Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MABs for m.3243A>G Mitochondrial Myopathy
NCT05063721Phase 1Completed
- Sponsor
- Maastricht University
- Start
- Mar 2020
- Primary completion
- Sep 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous mesoangioblasts in mitochondrial myopathy (MM) (2 arms), sponsored by Maastricht University. Primary endpoints: Blood flow in lower leg following intra-arterial delivery at Day 1, Adverse events following intra-arterial delivery at 1 month and 2 more. Started Mar 2020; status: completed.
02
Drugs
autologous mesoangioblasts
03
Conditions
mitochondrial myopathy (MM)
Beyond the preview
Go deeper on NCT05063721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063721.